The endocannabinoid system plays a central role in headache disorders, and targeting it could offer new treatments | Research

The takeaway

A comprehensive review found that the endocannabinoid system regulates key processes underlying headaches including trigeminovascular activity, pain control, and neuroinflammation, with sex differences shaping treatment responses.

Headache researchers, neurologists, pharmacologists developing cannabinoid therapies

Endocannabinoid degradation inhibitors consistently reduce headache-like behaviors in preclinical models

What the researchers found

The endocannabinoid system modulates trigeminovascular firing, CGRP release, neurogenic inflammation, cortical spreading depression, and glial activation after brain injury. Drugs that inhibit endocannabinoid breakdown (FAAH, MAGL, COX-2 inhibitors) consistently reduce headache-like behaviors in animal models. Endocannabinoid system dysregulation contributes to central sensitization in medication overuse headache. Females show distinct hormonal regulation, receptor expression, and glial activation that influence responses to cannabinoid-based therapies.

Why it matters

Headache disorders affect over a billion people globally and remain difficult to treat. The endocannabinoid system offers multiple therapeutic targets that could complement or replace existing treatments, particularly for patients who do not respond to conventional therapies.

The numbers in context

CB1 and CB2 receptors; endogenous ligands AEA and 2-AG; FAAH, MAGL, and COX-2 as drug targets; 5 headache types reviewed; sex-dependent responses documented

How the study worked

Comprehensive narrative review synthesizing preclinical and translational research on the endocannabinoid system across multiple headache types: migraine, tension-type headache, trigeminal autonomic cephalalgias, post-traumatic headache, and medication overuse headache.

What this study cannot tell us

Mostly based on preclinical data. Clinical evidence for endocannabinoid-targeted headache treatments is limited. Sex differences are documented but not yet integrated into clinical protocols. Individual variation in endocannabinoid tone may complicate treatment.

How to read the evidence

Moderate: comprehensive synthesis of preclinical evidence across multiple headache types, but limited clinical data supporting therapeutic translation.

When this study was published

2026 review of endocannabinoid system research in headache disorders.

The bigger picture

Rather than using whole cannabis for headaches, this review points toward more targeted strategies: enhancing the body's own endocannabinoid tone through enzyme inhibition. This approach could provide therapeutic benefit without the psychoactive effects of THC.

Questions still open

Would FAAH inhibitors be effective for migraine prevention in humans? Can peripheral endocannabinoid modulators treat headache without central nervous system side effects? How should sex differences be incorporated into endocannabinoid-based headache therapy?

Common questions

Can the endocannabinoid system treat headaches?

Preclinical research shows that enhancing endocannabinoid tone (by blocking the enzymes that break down the body's own cannabinoids) consistently reduces headache-like symptoms in animal models. Clinical translation is still in early stages.

Do men and women respond differently to cannabinoid headache treatments?

Yes. Females show distinct hormonal regulation of the endocannabinoid system, different receptor expression patterns, and unique glial activation, all of which influence how they respond to cannabinoid-based interventions.

Read the original research

Endocannabinoid Modulation in Headache: Mechanisms, Models, and Translational Therapies.

Cells, 15(4)

View on PubMed ↗Publisher’s paper ↗

Citation

Wen, Jie; Zhang, Yumin. (2026). Endocannabinoid Modulation in Headache: Mechanisms, Models, and Translational Therapies.. Cells, 15(4). https://doi.org/10.3390/cells15040331